Gilenya Rebound?

[Marco]

Study Identifies MS Patients at Risk of Severe Disease Reactivation After Gilenya Is Discontinued

Fingolimod withdrawal may trigger the return of pretreatment disease activity. It is difficult to identify patients at risk of disease reactivation. We compared the demographic and clinical features of patients experiencing severe disease reactivation (SDR) after fingolimod cessation with those of patients who did not.

https://insights.ovid.com/crossref?a...01801000-00003

[BikeChik]

Marco,thanks for this info. Sounds like neuros need to figure out a safe gilenya discontinuation method so high risk patients don't end up worse off when switching to a new therapy.